Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose folic acid in H-type hypertension by MTHFR C677T genotype
ChiCTR2300073217Phase 4Not yet recruiting
- Sponsor
- The Second Affiliated Hospital of Nanjing Medical University
- Start
- Aug 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of folic acid in hypertension (HTN) and hyperhomocysteinemia (2 arms), sponsored by The Second Affiliated Hospital of Nanjing Medical University. Primary endpoint: homocysteine concentrations. Planned start Aug 2023; status: not yet recruiting.
02
Drugs
folic acid
03
Conditions
hypertension (HTN)hyperhomocysteinemia
Beyond the preview
Go deeper on ChiCTR2300073217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300073217.